Posts by Pia
Therapeutic Antibody Treatment Options for Relapse/Refractory Neuroblastoma
Many clinical trials of anti-GD2 antibodies have been conducted, testing the antibodies as both standalone treatments or in combination with other drugs, such as immune-stimulating cytokines. Anti-GD2 antibodies have been approved for maintenance after reaching the first remission and for relapsed or refractory disease.
Read MoreHow a Child with Cancer Can Qualify for Social Security Benefits
There are a number of federal and state resources available to help families with limited income cover extra expenses while their child is sick. If your child qualifies for disability, he or she may be eligible for Supplemental Security Income (SSI) and Medicaid, even if already covered by another insurance.
Read MoreSarcoma in Children
A sarcoma is a cancer that develops in bone or soft tissue. Soft tissue is the connective tissue between body parts and organs and can include muscles, tendons, fat, bone and cartilage, blood vessels, and lymph vessels. Sarcomas can be found anywhere in the body, but they are most often found in the arms, legs, chest, or abdomen. Pediatric sarcoma is sarcoma occurring in children, and accounts for approximately 15% of pediatric cancer cases, with 1,500 to 1,700 new cases diagnosed each year.
Read MoreNeuroblastoma Cancer Tumor in Children
Neuroblastoma is diagnosed in approximately 800 children in the United States each year. Ninety percent of cases occur in children under five years old, though the average age of diagnosis is between one and two years old. Still, because neuroblastomas form from fetal nerve cells, children as young as newborns can develop tumors, and neuroblastoma accounts for 50% of all cancer cases in infants.
Read MoreLandmark Transatlantic Trial for Children with High-Risk Neuroblastoma Funded by Parent-Led Charities
In a landmark in pediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time, following the award of $1.4M to fund a new transatlantic clinical trial.
Read MoreWhy Research Childhood Cancers with Low Survival Rates?
Researching Childhood Cancers with Low Survival Rates The Rare Diseases Act of 2002 states that a disease or disorder is considered “rare” if fewer than 200,000 people are affected by it in the United States. Of more than 100 types of cancer[1], only breast and prostate cancers do not qualify as a “rare disease.”…
Read MoreRare Brain Tumors in Kids
Brain and spinal cord tumors, also known as central nervous system (CNS) tumors, are the most common type of solid tumors affecting children. Brain tumors make up about 15% of pediatric cancers, and are the second most commonly diagnosed cancer in children and now, the deadliest type of childhood cancer, ahead of leukemia.
Read MoreGive Hope & Love
When the world entered the COVID-19 pandemic, all we needed was a little Hope & Love. We asked all of our young ambassadors to share their messages of hope to the world. A big thank you to all of the frontline workers who risked their lives during the world pandemic. From all of us at Solving Kids’ Cancer
Read MoreLace Up For Kids 2019: Childhood Cancer Awareness Month
The “Lace Up For Kids” campaign connected childhood cancer supporters and advocates both nationally and internationally. For the month of September, thousands of gold shoelaces were shipped and worn to help raise awareness for Childhood Cancer Awareness Month. Take a look at some of the people who participated – you may even recognize some influencers and celebrities!
Read MoreClinical Trial Harnesses Power of Natural Killer Cells to Treat Neuroblastoma
Solving Kids’ Cancer, The Catherine Elizabeth Blair Memorial Foundation, and Wade’s Army awarded a $136,000 grant to support the novel immunotherapy clinical trial for childhood cancer. Researchers will use a humanized monoclonal antibody linked to IL2, known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them, while the IL2 activates NK cells…
Read More